Template:Risk_of_breast_cancer_with_menopausal_hormone_therapy_by_duration_in_large_observational_studies

Template:Risk of breast cancer with menopausal hormone therapy by duration in large observational studies

More information Study, Therapy ...

This article uses material from the Wikipedia article Template:Risk_of_breast_cancer_with_menopausal_hormone_therapy_by_duration_in_large_observational_studies, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.

Study	Therapy	Hazard ratio (95% CITooltip confidence interval)
E3N-EPIC: Fournier et al. (2005)^a	Transdermal estrogen plus progesterone <2 years 2–4 years ≥4 years	0.9 (0.6–1.4) 0.7 (0.4–1.2) 1.2 (0.7–2.0)
	Transdermal estrogen plus progestin <2 years 2–4 years ≥4 years	1.6 (1.3–2.0) 1.4 (1.0–1.8) 1.2 (0.8–1.7)
	Oral estrogen plus progestin <2 years 2–4 years ≥4 years	1.2 (0.9–1.8) 1.6 (1.1–2.3) 1.9 (1.2–3.2)
E3N-EPIC: Fournier et al. (2008)	Estrogen plus progesterone <2 years 2–4 years 4–6 years ≥6 years	0.71 (0.44–1.14) 0.95 (0.67–1.36) 1.26 (0.87–1.82) 1.22 (0.89–1.67)
	Estrogen plus dydrogesterone <2 years 2–4 years 4–6 years ≥6 years	0.84 (0.51–1.38) 1.16 (0.79–1.71) 1.28 (0.83–1.99) 1.32 (0.93–1.86)
	Estrogen plus other progestogens <2 years 2–4 years 4–6 years ≥6 years	1.36 (1.07–1.72) 1.59 (1.30–1.94) 1.79 (1.44–2.23) 1.95 (1.62–2.35)
E3N-EPIC: Fournier et al. (2014)	Estrogens plus progesterone or dydrogesterone <5 years ≥5 years	1.13 (0.99–1.29) 1.31 (1.15–1.48)
E3N-EPIC: Fournier et al. (2014)	Estrogen plus other progestogens <5 years ≥5 years	1.70 (1.50–1.91) 2.02 (1.81–2.26)
Footnotes: ^a = Oral estrogen plus progesterone was not analyzed because there was a low number of women who used this therapy. Sources: Main: ^[1] Additional: ^[2]^[3]^[4]

Template:Risk of breast cancer with menopausal hormone therapy by duration in large observational studies